Innovations


Stephen Mayfield

UCSD’s Steven Mayfield

Algae Collaboration Developing Therapeutic Proteins

Excerpted from Bruce V. Bigalow’s recent article in Xconomy.
AlgaeIndustryMagazine.com

Scientists from Sapphire Energy, UCSD, Scripps, and Protelica, have demonstrated the feasibility of using algae to produce commercial levels of human therapeutic proteins that are currently being used to treat emphysema and blog.allstream.com other diseases, or are in clinical trials for use to usefull link boost the immune system.

“The bottom line from the study is that the algae expression platform is click now ready for prime time,” according to UC San Diego biologist Stephen Mayfield. “We can express a very high percentage of recombinant genes — at least as good as the best system out there — and they are soluble and bioactive.”

Chlamydomonas

Chlamydomonas reinhardtii is used widely as a genetic model organism. The scientists in these studies said that the percentage of human proteins produced in their algal cultures that were properly folded in three dimensions was comparable to the fraction produced by mammalian cell cultures and much better than that produced by bacterial systems. And because algae generate their energy from sunlight and have relatively simple nutrient needs, they said the costs for using them at large scale to commercially produce human proteins should be much lower than for mammalian cell culture, which require expensive fermentation facilities.
With expected improvements in the visit web site ability to express proteins in algae, and the continued reduction in algal biomass cost associated with the large scale efforts to use algae for biofuel production, the scientists anticipate at least a ten-fold reduction in the costs over the next few years, which should make algal protein production the least expensive platform available. This reduced cost of just try! goods, coupled with an ability to rapidly scale production in inexpensive bioreactors, suggests that algae may become an economically superior platform for therapeutic protein production in the future.

Mayfield says the findings substantiate that algae could dramatically cut the costs of making complex proteins, including interferons, antibodies, and growth factors that already are being used to treat cancer and other diseases. Such complex drugs are currently produced from mammalian or bacterial cells. Algae, though, is much less expensive to work with, and algae cells grow much more quickly—doubling in number every 12 hours.

“Obviously the scalability and cost of algae make the system attractive but, if you can’t make a high percentage of proteins, then costs don’t really matter that much,” says Mayfield, who led the study. The research, published online in Plant Biotechnology Journal, included scientists from The Scripps Research Institute (TSRI), San Diego algae biofuels company Sapphire Energy, and Protelica, (previously known as ProtElix) a Hayward, CA-based startup that specializes in protein engineering. Mayfield joined UCSD in November from TSRI, where he had worked since 1987.

chlamydomonas

UC San Diego researchers found this alga, seen from the neck of this flask, can also produce human therapeutic proteins.

Mayfield said a few months ago that a factory that uses algae to produce biotechnology drugs would be significantly cheaper to mavericktester.com build than a traditional facility, and drug production costs would be about 75 percent lower. He contends that pharmaceutical companies could use such savings to dramatically cut the costs of some drugs that now cost consumers tens of thousands of dollars a year.

The process the scientists used to genetically modify a garden-variety green algae known as Chlamydomonas reinhardtii, was not universally successful. Of seven proteins that the group selected, Mayfield says the algae expressed four at levels sufficient for commercial production. “No one is really sure why some protein express and other don’t — that’s just the way it goes in all expression systems, ours included,” Mayfield says.

Chlamydomonas reinhardtii

Flasks of Chlamydomonas reinhardtii are shaken in the UCSD laboratory to enhance growth

Mayfield, an expert in the genetics of algae, is a co-founder of we choice the San Diego Center for Algae Biotechnology and we choice a scientific co-founder of Sapphire, which is developing algae-based biofuels with funding from Bill Gates’ Cascade Investments, Arch Venture Partners, and others. According to Mayfield the researchers filed patents on the technology and Sapphire holds the license.

Two years ago, Sapphire acquired Rincon Pharmaceuticals, a biotech that Mayfield co-founded to commercialize his research—which included recombinant DNA techniques for inserting human genes into algae, prompting the cells to make human proteins. Mayfield hopes to launch an algae protein expression company this year to commercialize the system, “and will be out pitching this to venture groups in the next few months.” —A.I.M.

Bruce V. Bigelow is the editor of Xconomy San Diego. You can e-mail him at bbigelow@xconomy.com or call 858-202-0492.

Photos: Beth Rasala, UCSD

Copyright ©2010 AlgaeIndustryMagazine.com. All rights reserved. Permission required to reprint this article in its entirety. Must include copyright statement and live hyperlinks. Contact editorial@algaeindustrymagazine.com.

FREE Algae News & Updates

Sign up to receive breaking A.I.M. updates!

From The A.I.M. Archives

— Refresh Page for More Choices
Phys.org reports that, in collaboration with the Berlin, Germany LED manufacturer FutureLED, scientists at the Technische Universität München have developed a unique comb...
Cyanobacteria, also known as blue-green algae because of their color, have endured for more than 2.5 billion years, providing ample time to adapt to changes in the Earth'...
Tess Riley writes in TheGuardian.com about how spirulina may be able to combat malnutrition in developing countries. Spirulina is one of the oldest life forms on Earth, c...
James Goodman writes in the democratandchronicle.com about Jeffrey Lodge, an associate professor of biological sciences at Rochester Institute of Technology, who knows wh...
As of March 1, 2015, bbi-biotech GmbH, of Berlin, Germany, has begun integrating IGV Biotech GmbH’s photobioreactors into its own life science product portfolio. A former...
Hammenhög, Sweden-based agribusiness Simris Alg has announced the launch of its first consumer products. The algae farmers’ exclusive omega-3 supplements and superfoods w...
Cellana, Inc., with operations in San Diego and Kailua-Kona, Hawaii, has announced that David Anton, Ph.D., has been appointed Chief Operating Officer and elected to the ...
Montague, Prince Edward Island-based Solarvest has announced that it has used its algal-based production platform to express bioactive therapeutic proteins. The proof of ...
As one of the most water-poor countries in the world, Jordan’s current water resources are significantly below the global water scarcity line. Annual rainfall falls under...
The European (FP7) algae project Sustainable PoLymers from Algae Sugars and Hydrocarbons (SPLASH) has been developing a platform technology for the conversion of third ge...
Brian Krassenstein, writing in 3Dprint.com, goes deeper into the recent paper in Engineering in Life Sciences journal discussing the impact 3D bioprinting will have in th...